secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0000950170-24-076460
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio receives FDA clearance for ADI-270 IND in renal cell carcinoma; Phase 1 trial planned for H2 2024
--------------------------------------------------------------------------------

- ADI-270 is the first gamma delta 1 CAR T cell therapy to enter clinical trials for solid tumors.
- Phase 1 multicenter, open-label trial in relapsed/refractory clear cell RCC to start in H2 2024; preliminary data expected H1 2025.
- ADI-270 is an armored allogeneic off-the-shelf CAR T targeting CD70+ cancers designed for high specificity and tumor infiltration.
- Trial will evaluate safety, tolerability, pharmacokinetics, overall response rate, duration of response, and disease control rate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024076460/0000950170-24-076460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024076460/acet-20240624.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-076460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer